

Journal of Materials Chemistry B

Materials for biology and medicine

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Hlushko, A. Marin, A. Chowdhury and A. K. Andrianov, *J. Mater. Chem. B*, 2025, DOI: 10.1039/D5TB02163D.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

ARTICLE

Macromolecular Dimensions of a Synthetic Polyelectrolyte as a Factor in its Interactions with Protein and Cells – Longer Chains are Favoured

Raman Hlushko, Alexander Marin, Ananda Chowdhury[#] and Alexander K. Andrianov^{*}Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

Understanding the mechanism of interactions between synthetic polyelectrolytes and ionic matter ubiquitous in living systems, such as proteins and cells, is a fundamental challenge and an important requirement for their clinical development as biomaterials and drug delivery systems. In contrast with small molecules or proteins, in which an active center or epitope largely defines the binding pattern, ionic polymers utilize a plurality of repeat units, which, individually, capable of only weak interactions with the target. Although, it can be expected that the effects of chain length and cooperativity play an important role in such interactions, this essential factor is often overlooked in practical research. Nevertheless, preclinical experience demonstrates the existence of activity - molar mass relationship for polyelectrolytes. Here, we focus on studying *in vitro* interactions of a clinical grade macromolecule - poly[di(carboxylatophenoxy)phosphazene] (PCPP), for which such relationship was already established *in vivo*. We found that polymers of various molar masses show different *in vitro* avidity to a model antigenic protein – lysozyme, with longer PCPP chains displaying lower dissociation constants and reduced entropic penalties. Higher molar mass polymers result in less compact complex morphologies, in which the protein was easier accessed by the antibody. The trend of greater *in vitro* activation of engineered immune cells with longer polymer chains was also observed. The results suggest that morphological and entropic benefits provided by higher molar mass polymers are critical in explaining previously observed *in vivo* trends, and such aspects should be prioritized in designing next generation macromolecular immunoadjuvants.

1. Introduction

Synthetic polyelectrolytes offer invigorating solutions for the development of multifunctional drug delivery systems and advanced biomaterials.¹⁻⁷ Their ability to spontaneously self-assemble with ionic counterparts has inspired numerous studies on the behavior of ionic macromolecules in solution, mechanisms of intermolecular complexation, and multilayer polyelectrolyte assembly.⁸⁻¹³ In depth understanding of the way these macromolecules interact with proteins and cells - ionic matters, which are ubiquitous in nature, is especially important. Not only this presents a fundamental challenge, but it is also a prerequisite for the successful advancement of ionic polymers into preclinical and clinical settings.^{14, 15}

Polyelectrolyte complexation, including the formation of complexes with proteins, is governed by a number of fundamental physico-chemical parameters, mainly by the choice of ionic pair and environmental conditions.¹⁶

Thermodynamically, polyelectrolyte interactions are dominated by favorable entropic contributions arising from the release of counterions, however the free energy of complex formation is also important for weak polyelectrolytes.¹⁷ Reactions of polyelectrolytes often involve mechanisms of cooperativity and associative charging. For example, a highly ionized polyelectrolyte can promote charging of its partner chain even under environmental conditions, which do not favor dissociation of the latter.^{17, 18}

Interactions of polyelectrolytes with proteins, which are amphoteric in nature, are characterized by some unique phenomena. While complex formation between polymer and protein carrying net charge of the opposite sign is a subject of most investigations, interactions on the “wrong side” of the isoelectric point were also reported.¹⁹⁻²² The binding of polyelectrolyte and a protein with both carrying like-charges becomes possible due to an uneven distribution of charges on the protein surface and flexibility of the polymer chain that can access those patches with sufficient efficiency.¹⁹⁻²² Macromolecular topology is yet another important parameter, which affects the way polyelectrolytes form complexes with proteins. In particular, polymers with complex star-shaped macromolecular architectures were reported to be less capable in protein-binding compared to their linear counterparts.²³ In depth understanding of polyelectrolyte-protein complexation is also a prerequisite for designing effective systems for intracellular delivery applications. Interactions of

^a Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA. E-mail: aandrianov@umd.edu

[#] Present address: PREMISE, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Gaithersburg MD 20878, USA

[†] Electronic supplementary information (ESI) available: Dynamic light scattering profiles, size exclusion chromatograms of polymers, isothermal titration calorimetry results.



ionic macromolecular carriers with membrane proteins can facilitate an uptake of therapeutic agents by cancer cells or stimulate immune-competent cells required for the effective performance of vaccines.^{14, 24} A relatively new strategy that utilizes ionic polymers and their avidity to proteins concerns cell surface engineering. Modification of cell surface with polyelectrolytes has been recently brought under development as a versatile platform that allows active modulation of cellular functions and creation of more realistic tissue structures.³

In studying interactions of polyelectrolytes with proteins and cells, one of the factors that is frequently overlooked is the length of a polymer chain. Nevertheless, the importance of this fundamental parameter has some significant practical implications. For instance, a member of a synthetic polyelectrolyte family - poly[di(carboxylatophenoxy)phosphazene] or PCPP, which has been advanced into clinical trials as part of vaccine formulations, has demonstrated a strong dependence of activity on its molar mass.²⁴ An increase in its chain length was reported to boost the *in vivo* immunostimulatory potency of this macromolecule.²⁵ The mechanism of such phenomenon has not been elucidated neither on the molecular, nor on the immunological pathway level. Gaining insights into the underlying reasons of such behavior may identify structural design parameters critical for the development of next generation polymers displaying superior immunoadjuvant activity. This knowledge may also improve the persistence of immune responses as polyphosphazene adjuvants are expected to lose activity as they undergo hydrolytic degradation with the formation of shorter chain fragments.

Here, we synthesized and characterized six PCPP samples with mass average molar masses ranging from 35 to 1,400 kDa. While studying their interactions with a model antigenic protein - hen egg lysozyme, we found that thermodynamic patterns of binding displayed by shorter chains are characterized with higher dissociation constants and pronounced entropy penalties. Investigation of complex aggregation profiles by dynamic light scattering (DLS) and lysozyme accessibility in complexes by antibody binding suggests more compact morphology for complexes formed by low molar mass polymers. Altogether, longer polymer chains showed higher avidity to lysozyme and superior ability to display antigenic protein, which can provide important clues to the understanding of PCPP behavior *in vivo*. Furthermore, in experiments with engineered immune cells *in vitro*, high molar mass PCPP samples were able to induce higher activation levels, which can be potentially explained by their greater avidity to proteins on cell surface.

2. Materials and Methods

2.1 Materials

Propylparaben, diglyme (anhydrous, 99.5%), potassium hydroxide (Sigma-Aldrich, St. Louis, MO), propylparaben sodium, NF (Spectrum Chemical Mfg. Corp., New Brunswick, NJ), hen egg lysozyme (BioUltra, lyophilized powder, ≥98%),

ethanol (200 proof, anhydrous) (The Warner-Graham Company, Cockeysville, MD) and phosphate buffered saline (PBS), pH 7.4 (Thermo Fisher Scientific, Waltham, MA) were used as received.

2.2. Synthesis of PCPP Samples with Variable Molar Masses

Synthesis of PCPP molar mass samples was carried out by reacting polydichlorophosphazene (PDCP) with propylparaben (n-propyl ester of p-hydroxybenzoic acid) with subsequent hydrolysis of ester functionalities.^{26, 27} To achieve variation in molar mass, propylparaben was utilized in quantities and under conditions that allowed for a controlled degradation of partially substituted polymer in the reaction. For example, a high molar mass PCPP H2 sample was synthesized using a propylparaben in a reaction with PDCP in an equivalent of 22 as follows. Propylparaben (40 g, 0.22 mol) was dispersed in 22 mL of diglyme and heated in a three-neck round-bottom flask at 110 °C under stirring until fully dissolved. Sodium propylparaben (44.8 g, 0.22 mol) was then added, and the mixture was stirred until complete dissolution. The solution was subsequently diluted with 90 mL of diglyme under continuous stirring. Then, a solution of PDCP (1.35 g, 0.02 mol of repeat unit) in diglyme (30 mL) was added dropwise to the reaction mixture using an addition funnel under a nitrogen atmosphere with constant stirring. The reaction was maintained at 110 °C for 2 h, then cooled to 95 °C and aqueous potassium hydroxide (13 M, 70 mL) was added slowly to the mixture. The resulting precipitate was dissolved in deionized water, precipitated by the addition of sodium chloride, redissolved in deionized water and precipitated again using ethanol. Other PCPP molar mass samples were synthesized similarly using the following propylparaben equivalents: H1 – 18:1, M2 – 5:1, M1 – 4.5:1, L2 – 3:1, L1 – 2.7:1.

2.3. Size-Exclusion Chromatography with Multiangle Light Scattering Detector (SEC-MALS)

Size exclusion chromatography with ultraviolet (UV), refractive index (RI), and multiangle light scattering detectors (MALS) was used to determine mass average and number average molar masses of PCPP samples. The SEC-MALS equipment consisted of a Vanquish Flex system (Thermo Fisher Scientific Inc, Waltham, MA, USA) equipped with refractive Index (OptiLab T-rEX, Wyatt Technologies, Santa Barbara, CA, USA), multiangle laser light scattering (MALS, Dawn HELEOS-II, λ = 658 nm, Wyatt Technologies, Santa Barbara, CA, USA) and dynamic light scattering (DLS, DynaPro NanoStar, Wyatt Technologies, Santa Barbara, CA, USA) detectors. Data acquisition and processing were performed using ASTRA software (Wyatt Technologies, Santa Barbara, CA, USA). Two SEC columns connected in series were employed for the analysis: a TSKgel GMPW (7.5mm x 30 cm, 17 μ m, TOSOH Bioscience LLC, Japan) and TSKgel G3000PW (7.8mm x 30 cm, 7 μ m, TOSOH Bioscience LLC, Japan). The samples were dissolved in PBS (pH 7.4) with a concentration of 1.0 mg/mL and filtered through a 0.22 μ m Nylon syringe filter prior to the analysis. PBS (pH 7.4) was filtered through 0.1 μ m PVDF filter and was used as an eluent. The following SEC conditions were used for each run: 1.0 mg/mL PCPP, 50 μ L



injection volume, 0.5 mL/min flow rate and 25°C column temperature.

2.4. Isothermal Titration Calorimetry (ITC)

The calorimetric titration was performed using a Nano ITC SV instrument (TA Instruments, Waters, New Castle, DE, USA) in an aqueous solution (50 mM phosphate buffer, pH 7.5). Polymer solution (0.125 mg mL⁻¹) was placed into an isothermal chamber and lysozyme solution (2.5 mg mL⁻¹) was used as a titrant. Thirty-two 8 µL injections were performed from a 250 µL syringe rotating at 36.7 rad s⁻¹ with a 300 s delay between each injection. A heat release curve (microjoules per second *versus* seconds), generated by each injection, was processed using NanoAnalyze software, version 3.12.5 (TA Instruments, Waters, New Castle, DE, USA) to yield the heat associated with each injection. The above software was also used for data analysis, and a single set of identical sites (SSIS) binding model was employed to calculate the thermodynamic parameters: binding constant (K_a), reaction stoichiometry (n), enthalpy (ΔH), and entropy (ΔS) changes.

2.5. Analysis of Protein-Antibody Binding in Lysozyme-PCPP Complexes

The accessibility of lysozyme in complexes formed by L1 and H1 polymers was tested using an enzyme-linked immunosorbent assay (ELISA) according to the methodology described previously.^{28, 29} A 96-well plate was coated overnight (4°C) with a solution (100 ng/mL, carbonate buffer, pH 9.2, 100 µL per well) of rabbit anti-chicken egg lysozyme antibody (Rockland Immunochemicals, Gilbertsville, PA). The coating solution was then removed, the wells were washed three times with PBS (pH 7.4) and then treated with a blocking buffer (1% BSA / 0.05% Tween-20 in PBS, 300 µL/well) for 1 h at 37°C. The blocking buffer was removed by rinsing wells four times with a washing buffer (0.05% Tween-20 in PBS). Complexes of two stoichiometries were prepared - (a) 0.096 mg/mL lysozyme with 0.72 mg/mL PCPP (1.5:1 lysozyme/-COOH, mmol/Eq) and (b) 0.08 mg/mL lysozyme with 0.368 mg/mL PCPP (2.5:1 lysozyme/-COOH, mmol/Eq) and serially diluted with PBS (pH 7.4) for the analysis. Each sample (50 µL) was reconstituted in the equivalent volume of a blocking buffer (2x concentration) and placed in the well. The plate was incubated at 37 °C for 1 h and then the wells were rinsed with a washing buffer. Next, peroxidase-conjugated rabbit anti-chicken egg lysozyme antibody (Rockland Immunochemicals, Gilbertsville, PA) in a blocking buffer (500 ng/mL) was added (100 µL/well), the plate incubated at ambient temperature for 1 h and wells were rinsed with a washing buffer. To develop a colorimetric reaction, 3,3',5,5'-tetramethylbenzidine (TMB) substrate (1-Step Ultra® TMB-ELISA, Thermo Scientific, Rockford, IL) was added (100 µL per well). The plate was left for 20 min at room temperature, and the reaction was stopped by adding sulfuric acid (1 M, 50 µL per well). The absorbance was measured at 450 nm using a Multiskan Spectrum Reader (Thermo Fisher Scientific, Waltham, MA). Each experiment was performed in triplicate.

2.6. Interactions of PCPP with Engineered Immune Cells

In vitro evaluation was conducted using engineered murine macrophages - RAW BLUE cells (InvivoGen, San Diego, CA) featuring an NF-κB/AP-1-inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. Cells were maintained in culture in Dulbecco's modified eagle medium containing glucose and L-glutamine (Thermo-Fisher Scientific, Grand Island, NY) supplemented with 10% fetal bovine serum (10%), penicillin streptomycin (1%) (Thermo-Fisher Scientific, Grand Island, NY) and normocin (100 µg/ml) (InvivoGen, San Diego, CA). PCPP samples of various molar masses and concentrations in culture were added to an equal volume of RAW BLUE cells in 96-well plates (120,000 cells/well) and incubated at 37°C in carbon dioxide (5%) for 20 h. The extent of the RAW BLUE cell activation was assessed spectrophotometrically by the conversion of SEAP substrate - p-nitrophenylphosphate (Millipore Sigma, St. Louis, MO). Culture supernatant was added to the reagent at one-to-ten ratio by volume. The absorbance (405 nm) was read using a ThermoScientific SpectraMax plate reader (Molecular Devices, San Jose, CA). Each experiment was performed in triplicate.


3. Results and Discussion

Binding and effective presentation of immunogenic proteins is one of the key prerequisites of contemporary vaccine delivery systems and immunoadjuvants.³⁰⁻³³ This enabling functionality is also fundamental to the adjuvantation effect of polyphosphazene macromolecules *in vivo*.^{24, 34, 35} However, the existence of a link between the loss of biological activity with the decrease in the molar mass observed in animal studies and the ability of PCPP to bind proteins is not yet established and the potential mechanism remains obscure. Searching for keys to understanding the underlying processes can facilitate the development of next generation polyphosphazene immunoadjuvants.

3.1. Synthesis of Polymers with Variable Chain Lengths Using Modulated In-Situ Degradation Approach

Synthesis of PCPP macromolecules with variable chain length was achieved via a controlled degradation of a polymer in a production process. A synthetic pathway to PCPP utilizes ring-opening polymerization process with a subsequent macromolecular substitution and deprotection reactions (Scheme 1a). This typically results in polymers with molar masses of approximately 1,000 kDa.²⁶ Macromolecules with shorter chain length were synthesized utilizing an incomplete substitution process, which yields polymers containing residual chlorine atoms in the substitution step. These 'weak links' are then hydrolyzed in the deprotection step resulting in a cleavage of the backbone and the formation of shorter polymer chains (Scheme 1b). Therefore, a synthetic lot, which did not contain sufficient amounts of nucleophilic agent – propyl paraben to complete the substitution results in a lower molar mass of the polymer. Accordingly, the greater deficiency of the reagent in the reaction mixture leads to a larger in-process polymer degradation and lower resulting molar mass. For each polymer





Scheme 1. Reaction pathways for the synthesis of PCPP with varying molar masses: (a) maximum afforded substitution of chlorine atoms with a nucleophile and (b) their deliberately incomplete substitution, which results in the production of weak links and polymer chain cleavage.

of this study, the required reagent ratios were found empirically using trial and error approach.

Using the procedures described above, six PCPP samples were synthesized and characterized (Table 1 and Figure S1). They were grouped according to mass average molar masses (M_w) determined by the SEC-MALS method: L1 and L2 (low – below 100 kDa), M1 and M2 (medium – between 100 and 1,000 kDa) and H1, H2 (high – above 1,000 kDa). DLS characterization results were in agreement with SEC-MALS data on the chain length hierarchy of synthesized samples (Table 1).

3.2. Higher Molar Mass Polymers Are Capable of Stronger Protein Binding and Their Self-Assembly is Less Penalized by Entropy Losses

Protein-binding properties of PCPP were studied using a hen egg lysozyme – a model vaccine antigen,^{29, 36, 37} which was proven to work with PCPP *in vivo*.³⁸ The results of isothermal titration calorimetry (ITC) analysis of interactions between PCPP and lysozyme are presented in Figure 1 and Figures S2-S7, Supporting Information. As seen from the comparison of dissociation constants, the avidity of PCPP to protein is practically similar for mid and high molar mass polymers, but

lower for shorter chain macromolecules – L1 and L2 (Figure 1a). As expected, the number of protein molecules associated with a single polymer chain is growing steadily as the molar mass of polymers increases (Figure 1b). The results indicate that it takes approximately 25-30 carboxylic acid groups of PCPP (12-15 repeat units) to bind a single lysozyme molecule. This number appears to be practically independent of the overall length of the polymer chain. The difference in the dissociation constant, which constitutes an increase of approximately one order of magnitude for shorter macromolecules, can be better understood from the comparison of thermodynamic patterns of interactions (Figure 1c). As seen from the Figure, in all cases, lysozyme-PCPP interactions are enthalpy driven, which is consistent with processes resulting from electrostatic or hydrogen bonding between complementary functional groups of the synthetic macromolecule and those on the protein surface.³⁹ This is generally consistent with interactions of negatively charged polymer and proteins with high isoelectric point.^{40, 41} However, the observed gains were not significantly different across the whole molar mass range to explain an increase in the dissociation constants of complexes formed by L1 and L2.

Table 1. Physico-chemical characteristics of PCPP samples.

N	Sample	SEC-MALS			DLS	
		M_n (kDa)	M_w (kDa)	$\bar{D}$	D_z (nm)	pdi
1	L1	30	35	1.2	14	0.4
2	L2	40	50	1.4	20	0.4
3	M1	120	160	1.4	25	0.2
4	M2	240	280	1.2	43	0.3
5	H1	810	1100	1.4	57	0.4
6	H2	1100	1400	1.2	63	0.3

SEC-MALS results: M_n and M_w – number average and mass average molar masses, $\bar{D}$ – dispersity; DLS results: D_z – z-average hydrodynamic diameter, pdi – polydispersity index.



ARTICLE




Figure 1. Isothermal titration calorimetry (ITC) results describing interactions between lysozyme and PCPP samples: (a) dissociation constants of resulting complexes, (b) their stoichiometry as described in a number of carboxylic acid groups per protein and proteins per PCPP chain, (c) thermodynamic patterns of interactions (DH – enthalpy change, DS – entropy change; favorable contributions are shown in green, unfavorable in red, 0.125 mg/mL PCPP (analyte), 2.5 mg/mL protein (titrant), 50 mM phosphate buffer, pH 7.5)

In a contrast to enthalpy changes, a significant difference is detected in entropy loss with a larger penalty found in the case of both low molar mass macromolecules (Figure 1c). The negative value of entropy change can be generally expected due to spatial constraints and compactization caused by complexation although this effect can be at least partially compensated owing to the release of counterions and water molecules.^{39, 42} Overall compactness of protein-polymers complexes and their water content are determined by a number of fundamental parameters, such as chain flexibility and protein isoelectric point, and can vary in a broad range.⁹ Therefore, the observed differences in entropy changes can be useful to review in the context of the mechanism of complex formation, its morphology and the effect of chain length on these parameters.

3.3. Polymer with Longer Chain Length Display Less Compact Morphology

The formation of protein-polymer complexes was studied by monitoring their dimensions and aggregation patterns using the dynamic light scattering (DLS) titration method. Figure 2 shows

changes in the z-average hydrodynamic diameters of PCPP samples of variable molar masses upon addition of lysozyme. DLS results display a rapid and dramatic increase in the complex size upon titration of short chain PCPP samples. As the molar mass of PCPP rises, it takes a gradually increasing amount of lysozyme to cause detectable changes in the DLS data. Concurrently, the slope of titration curves becomes significantly less steep indicating lower trend to aggregation in case of high molar mass polymers (Figure 2). This suggests the formation of complexes with higher water content and less compact morphology – agglomerates, rather than aggregates. It is generally expected that polymers of sufficient length realize their binding capability by wrapping and winding around proteins and particles.⁴³⁻⁴⁶ This imminently results in the formation of macromolecular conformations containing multiple loops and tails or gel-like structures⁴⁷ (Figure 2, right side). In contrast, macromolecules, which are too short to provide for such loose irregularities, are more likely to act as crosslinkers connecting proteins in a much denser, aggregated network^{43, 46-49} (Figure 2, left side). The latter process results in






Figure 2. DLS titration of PCPP of variable molar masses with lysozyme. The results presented as the ratio between z-average hydrodynamic diameters of complexes and PCPP samples (50 mM phosphate buffer, pH 7.4, 2 mg/mL PCPP, ambient temperature). Dense protein-polymer aggregates formed by short chain PCPP and loose agglomerates of long chain PCPP are schematically shown.

significantly greater entropic penalties compared to the formation of looser assemblies of longer polymer chains. Higher charge density in aggregated systems may also result in an improved retention of counterions, which can contribute to unfavorable entropy changes observed in case of short polymer chains.⁵⁰

3.4. Complexes Formed by Shorter Chains Show Reduced Accessibility of the Protein

Further analysis of complexes involved the assessment of protein accessibility using antibody binding experiments. Potential differences in the detection of polymer-bound lysozyme by enzyme-linked immunosorbent assay (ELISA) may

indicate variations in the morphology of complexes and either support or undermine the importance of results revealed by DLS and ITC studies. The ability of the complex to provide efficient exposure of protein is also important from the practical standpoint. The vaccine delivery function of polyphosphazene immunoconjugates is largely dependent on the ability of the polymer to make antigenic protein “visible” to the immune system.

Therefore, the accessibility of protein in complexes formed by L1 and H1 polymers was evaluated based on the ability of complex-bound lysozyme to interact with both capturing and detecting antibody. Figure 3 a, b shows ELISA assay response at serial dilutions for complexes formed by L1 (brown columns)




Figure 3. Accessibility of lysozyme in its complexes with high molar mass (H1) and low molar mass PCPP (L1) as evaluated by ELISA using lysozyme antibodies at (a) 1.5:1 and (b) 2.5:1 (mmol/Eq) protein-to-carboxylic acid group ratios and (c) schematics of a potential effect of complex morphology on ELISA results (experimental results are shown as optical densities at 450 nm (brown columns – complexes formed by L1, blue – by H1, left axes) or their ratios expressed as percents (green lines, right axes), $n=3$, error bars - standard error).






Figure 4. Immunoactivation of RAW Blue cells by PCPP samples of various molar masses as measured by the spectrophotometric monitoring of SEAP substrate hydrolysis: experimental results presented as a function of (a) polymer concentration and (b) z-average hydrodynamic diameter of PCPP in PBS, pH 7.4 (405 nm, $n=3$, error bars - standard error).

and H1 (blue columns) at two different protein-to-polymer ratios. The results demonstrate striking differences between L1 and H1-derived complexes of both compositions and at all concentrations. The ability of antibodies to detect lysozyme bound to shorter chains is greatly suppressed compared to complexes formed by their longer counterparts. Even under the most favorable conditions the fraction of antibody-recognized protein in L1-formed complexes does not exceed 30 percent of that detected in H1-derived samples (green lines and diamond symbols in Figure 3a, b). These findings are in line with the hypothesis that compact morphology of complex aggregates formed by short chain PCPP is responsible for the effects observed in DLS and ITC studies. In fact, a loose conformation of a polymer chain should facilitate the access of antibodies to lysozyme as schematically shown in Figure 3c.

3.5. Larger PCPP Macromolecules Provide for Enhanced Stimulation of Engineered Immune Cells

Another important aspect of biological activity inherent to polyphosphazene polyelectrolytes is in their ability to interact with the cellular surface. It has been shown that various PCPP

copolymers facilitate the uptake of protein cargo into endothelial and cancer cells via multiple endocytic pathways.⁵¹ Intrinsic to immunostimulating properties of PCPP and its structural analogs is their ability to stimulate immune cells, such as human dendritic cells,⁵² or induce production of cytokines in mouse spleen cells.⁵³

Engineered immune cells expressing pattern recognition receptors (PRRs) present a convenient model for studying PCPP-cell interactions. It has been demonstrated that RAW BLUE cells, which are derived from murine macrophages, can be effectively stimulated by PCPP.³⁵ Furthermore, secreted embryonic alkaline phosphatase (SEAP) reporter construct harbored in such cells enables UV-Vis readouts allowing a straightforward evaluation of the effect of various polymer-related parameters. Importantly, PCPP induced cell activation has been associated with the ability of PCPP to bind solubilized membrane PRRs, suggesting the potential role of surface proteins in facilitating polymer – cell interactions.³⁵ *In vitro* assessment of the ability of PCPP samples with varying molar mass to stimulate RAW Blue cells demonstrated a striking effect of the polymer chain length (Figure 4). An increase in molar mass of PCPP samples leads to



ARTICLE

Journal Name

a gradually stronger immunostimulating activity. Although this phenomenon requires further in-depth investigations using other cell types and environmental conditions, the results uncover similar trends to those observed in studying polymer protein self-assembly – the larger polymer size is favored. These findings underline the importance of a systematic review of polymer-induced cellular activation in the context of polymer binding to surface proteins and receptors.

4. Conclusion

Pre-clinical and clinical advancement of synthetic polyelectrolytes has seen significant acceleration in recent years. This progress is largely associated with important innovations in the area of polyelectrolyte self-assembly with applications ranging from biocompatible multilayer coatings to engineered cells. In the field of drug and vaccine delivery, the involvement of synthetic biodegradable polyelectrolytes with benign degradation by-products opened a potential pathway to their safe clinical use. Water-soluble polyphosphazene polyelectrolyte, PCPP with a clinically proven safety and immunoadjuvant potency is one of the most promising macromolecules of this generation. Mechanistically, PCPP functions via its self-assembly with an immunogen and its effective presentation to the immune system. One of unexplained and intriguing features of its behavior remained in a rapid loss of its *in vivo* activity, which was experimentally observed when a molar mass decreased below 100 kDa threshold. The adverse impact of this property is not only in the limitation on utilizing only high molar mass polymers in clinical settings. It also results in a shortened activity window as hydrolytic degradation of the polymer leads to a simultaneous loss of its potency.

The above *in vitro* findings shift a spotlight from focusing entirely on the stability of PCPP complexes with the protein to emphasizing morphological aspects of the complex formed and accessibility of the antigenic protein embedded in its agglomerated matter. Longer polymer chains appear to create additional benefits for the application through creating looser and more accessible assemblies potentially resulting in a more effective antigen presentation *in vivo*. Perhaps such agglomerated matter can also be easier recognized by immune cells, as follows from the results of *in vitro* cellular assays. Regardless of the exact mechanism, results suggest the importance of creating looser complex morphology to enhance antigen presentation feature of the complex and its cellular recognition. Therefore, the rational approach to a structural design of a new generation polyphosphazene adjuvants calls for an inclusion of hydrophilic moieties so that the formation of compact aggregates under *in vivo* conditions can be avoided. Although the above study was focused on a single example of a synthetic polyelectrolyte, it can be envisioned that similar aspects should be explored when other ionic macromolecules undergo exposure to protein and cellular environment while carrying out vaccine or drug delivery functions.

Author contributions

Conceptualization: A.K.A.; investigation: R.H., A.M., and A.C.; data curation, formal analysis: R.H., A.M. and A.C.; writing—original draft preparation, writing—review and editing, supervision, project administration, funding acquisition: A.K.A.

View Article Online

DOI: 10.1039/D5TB02163D

Conflicts of interest

Alexander K. Andrianov is a shareholder of NeulImmune, Inc. – the company that develops HCV vaccine. The company had no role in the design of the study, collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results. This potential conflict of interest has been disclosed and are managed by the University of Maryland, College Park. The other authors have no conflicts of interest to report.

Data availability

The data supporting this article have been included as part of the Supplementary Information.

Acknowledgements

This work was supported in part by the National Institutes of Health Grants 1R01AI168048-01 (A.K.A.), R01AI175439 (A.K.A.) and 1U19AI181930-01 (A.K.A.). Access to SEC-MALS was provided by the Biomolecular Labeling Lab (BL2) at the Institute for Bioscience and Biotechnology Research (IBBR), supported under the NIST CA grant 70NANB21H105.

References

- 1 L. Zhao, M. Skwarczynski and I. Toth, *ACS Biomater. Sci. Eng.*, 2019, **5**, 4937-4950.
- 2 A. K. Andrianov, in *Prog. Mol. Biol. Transl. Sci.*, ed. D. B. Teplow, Academic Press, 2025, vol. 212, pp. 235-259.
- 3 P. Zhang, M. L. Bookstaver and C. M. Jewell, *Polymers*, 2017, **9**, 40.
- 4 E. Hasan, C. J. Lewis, J. G. Hernandez, P. Gentile and A. M. Ferreira, *RSC Adv.*, 2025, **15**, 13908-13923.
- 5 D. J. Dowling and O. Levy, *Pediatr. Infect. Dis. J.*, 2015, **34**, 1395-1398.
- 6 D. Alkekhia, P. T. Hammond and A. Shukla, *Annu. Rev. Biomed. Eng.*, 2020, **22**, 1-24.
- 7 Z. Deng, Q. Shi, J. Tan, J. Hu and S. Liu, *ACS Mater. Lett.*, 2021, **3**, 1339-1356.
- 8 M. Muthukumar, *Macromolecules*, 2017, **50**, 9528-9560.
- 9 S. Gao, A. Holkar and S. Srivastava, *Polymers*, 2019, **11**, 1097.
- 10 J. Fu and J. B. Schlenoff, *J. Am. Chem. Soc.*, 2016, **138**, 980-990.
- 11 A. E. Marras, J. M. Ting, K. C. Stevens and M. V. Tirrell, *J. Phys. Chem. B*, 2021, **125**, 7076-7089.
- 12 F.-X. Xiao, M. Pagliaro, Y.-J. Xu and B. Liu, *Chem. Soc. Rev.*, 2016, **45**, 3088-3121.
- 13 J. J. Richardson, J. Cui, M. Björnalm, J. A. Braunger, H. Ejima and F. Caruso, *Chem. Rev.*, 2016, **116**, 14828-14867.



- 14 K. Achazi, R. Haag, M. Ballauff, J. Darnedde, J. N. Kizhakkedathu, D. Maysinger and G. Multhaup, *Angew. Chem., Int. Ed.*, 2021, **60**, 3882-3904.
- 15 R. S. Fisher, J. Liao, S. Y. Ahn, N. Modi, A. K. Kidane and A. C. Obermeyer, *Annu. Rev. Chem. Biomol. Eng.*, 2025, **16**, 119-145.
- 16 S. M. Lalwani, C. I. Eneh and J. L. Lutkenhaus, *Phys. Chem. Chem. Phys.*, 2020, **22**, 24157-24177.
- 17 V. S. Rathee, H. Sidky, B. J. Sikora and J. K. Whitmer, *J. Am. Chem. Soc.*, 2018, **140**, 15319-15328.
- 18 V. S. Rathee, A. J. Zervoudakis, H. Sidky, B. J. Sikora and J. K. Whitmer, *J. Chem. Phys.*, 2018, **148**.
- 19 A. B. Kayitmazer, D. Seeman, B. B. Minsky, P. L. Dubin and Y. Xu, *Soft Matter*, 2013, **9**, 2553-2583.
- 20 C. Yigit, J. Heyda, M. Ballauff and J. Dzubiella, *The Journal of Chemical Physics*, 2015, **143**, 064905.
- 21 X. Xu, S. Angioletti-Uberti, Y. Lu, J. Dzubiella and M. Ballauff, *Langmuir*, 2019, **35**, 5373-5391.
- 22 J. M. Horn, R. A. Kapelner and A. C. Obermeyer, *Polymers*, 2019, **11**, 578.
- 23 A. Nieto-Orellana, M. Di Antonio, C. Conte, F. H. Falcone, C. Bosquillon, N. Childerhouse, G. Mantovani and S. Stolnik, *Polym. Chem.*, 2017, **8**, 2210-2220.
- 24 A. K. Andrianov and R. Langer, *J. Controlled Release*, 2021, **329**, 299-315.
- 25 L. G. Payne, S. A. Jenkins, A. L. Woods, E. M. Grund, W. E. Geribo, J. R. Loebelenz, A. K. Andrianov and B. E. Roberts, *Vaccine*, 1998, **16**, 92-98.
- 26 A. K. Andrianov, Y. Y. Svirkin and M. P. LeGolván, *Biomacromolecules*, 2004, **5**, 1999-2006.
- 27 A. K. Andrianov, J. Chen and M. P. LeGolván, *Macromolecules*, 2004, **37**, 414-420.
- 28 M. Lueckheide, A. Marin, H. D. Tagad, N. D. Posey, V. M. Prabhu and A. K. Andrianov, *ACS Polym. Au*, 2023, **3**, 354-364.
- 29 I. Z. Romero Méndez, Y. Shi, H. HogenEsch and S. L. Hem, *Vaccine*, 2007, **25**, 825-833.
- 30 T. J. Moyer, Y. Kato, W. Abraham, J. Y. H. Chang, D. W. Kulp, N. Watson, H. L. Turner, S. Menis, R. K. Abbott, J. N. Bhiman, M. B. Melo, H. A. Simon, S. Herrera-De la Mata, S. Liang, G. Seumois, Y. Agarwal, N. Li, D. R. Burton, A. B. Ward, W. R. Schief, S. Crotty and D. J. Irvine, *Nat. Med.*, 2020, **26**, 430-440.
- 31 D. Laera, H. HogenEsch and D. T. O'Hagan, *Pharmaceutics*, 2023, **15**, 1884.
- 32 L. A. Brito, P. Malyala and D. T. O'Hagan, *Semin. Immunol.*, 2013, **25**, 130-145.
- 33 R. A. Schwendener, *Ther. Adv. Vaccines*, 2014, **2**, 159-182.
- 34 A. K. Andrianov, A. Marin and B. E. Roberts, *Biomacromolecules*, 2005, **6**, 1375-1379.
- 35 A. K. Andrianov, A. Marin and T. R. Fuerst, *Biomacromolecules*, 2016, **17**, 3732-3742.
- 36 V. V. Temchura, D. Kozlova, V. Sokolova, K. Überla and M. Epple, *Biomaterials*, 2014, **35**, 6098-6105.
- 37 H. Akiba, H. Tamura, M. Kiyoshi, S. Yanaka, K. Sugase, J. M. M. Caaveiro and K. Tsumoto, *Sci. Rep.*, 2019, **9**, 15481.
- 38 J. Kovacs-Nolan, J. W. Maplettoft, L. Latimer, L. A. Babiuk and S. v. D. L.-v. d. Hurk, *Vaccine*, 2009, **27**, 2048-2054.
- 39 X. Wang, K. Zheng, Y. Si, X. Guo and Y. Xu, *Polymers*, 2019, **11**, 82.
- 40 X. Du, P. L. Dubin, D. A. Hoagland and L. Sun, *Biomacromolecules*, 2014, **15**, 726-734.
- 41 Y. Xu, M. Mazzawi, K. Chen, L. Sun and P. L. Dubin, *Biomacromolecules*, 2011, **12**, 1512-1522.
- 42 S. Yu, X. Xu, C. Yigit, M. van der Giet, W. Zidek, J. Jankowski, J. Dzubiella and M. Ballauff, *Soft Matter*, 2015, **11**, 4630-4639.
- 43 F. Capito, H. Kolmar, B. Stanislawski and R. Skudas, *J. Polym. Res.*, 2014, **21**, 346.
- 44 P. Chodanowski and S. Stoll, *Macromolecules*, 2001, **34**, 2320-2328.
- 45 R. Messina, C. Holm and K. Kremer, *Langmuir*, 2003, **19**, 4473-4482. [DOI: 10.1039/D5TB02163D](https://doi.org/10.1039/D5TB02163D)
- 46 A. Akinchina and P. Linse, *Macromolecules*, 2002, **35**, 5183-5193.
- 47 J. Gummel, F. Cousin and F. Boué, *Macromolecules*, 2008, **41**, 2898-2907.
- 48 M. Karayianni, S. Pispas, G. D. Chryssikos, V. Gionis, S. Giatrellis and G. Nounesis, *Biomacromolecules*, 2011, **12**, 1697-1706.
- 49 D. Takahashi, Y. Kubota, K. Kokai, T. Izumi, M. Hirata and E. Kokufuta, *Langmuir*, 2000, **16**, 3133-3140.
- 50 G. S. Manning, *Phys. A* 1996, **231**, 236-253.
- 51 B. Qamar, M. Solomon, A. Marin, T. R. Fuerst, A. K. Andrianov and S. Muro, *Pharmaceutics*, 2021, **13**, 249.
- 52 C. D. Palmer, J. Ninković, Z. M. Prokopowicz, C. J. Mancuso, A. Marin, A. K. Andrianov, D. J. Dowling and O. Levy, *Biomaterials*, 2014, **35**, 8876-8886.
- 53 S. Awate, N. Eng, V. Gerdts, L. Babiuk and G. Mutwiri, *Vaccines*, 2014, **2**, 500-514.



Data availability Statement

The data supporting this article have been included as part of the Supplementary Information.

